Citations

Clear

4847 citation(s) found for "Tu, Eric".

Trends in the Association Between Age and In-Hospital Mortality After Percutaneous Coronary Intervention
Peterson, Eric D., Roe, Matthew T. , Spertus, John A. , Rumsfeld, John S., Anderson, H. Vernon, Klein, Lloyd W. , Holmes, David R. , Singh, Mandeep , Ou, Fang‐Shu , Ho, Kalon K.L. , Spertus, John A

Mayo Clinic

Circulation: Cardiovascular Interventions | February 11, 2009 | Volume: 2 | Issue: 1 | Pages: 20-26

10.1161/circinterventions.108.826172 | PMID 20031689 Get It

Background— Temporal trends and contemporary data characterizing the impact of patient age on in-hospital outcomes of percutaneous coronary interventions are lacking. We sought to determine the importance of age by assessing the in-hospital mortality of stratified age groups in the National Cardiovascular Data Registry. Methods and Results— In-hospital mortality after percutaneous coronary intervention on 1 410 069 patients was age stratified into 4 groups—group 1 (age <40, n=25 679), group 2 (40 to 59, n=496 204), group 3 (60 to 79, n=732 574), and group 4 (≥80, n=155 612)—admitted from January 1, 2001, to December 31, 2006. Overall in-hospital mortality was 1.22%; in-hospital mortality was 0.60%, 0.59%, 1.26%, and 3.16% in groups 1 to 4, respectively, P <0.0001. Overall temporal improvement per calendar year in the adjusted in-hospital mortality after percutaneous coronary intervention was noted in most groups; however, this finding was significant only in the 2 older age groups, group 3 (odds ratio, 0.94; 95% CI, 0.92 to 0.96) and group 4 (odds ratio, 0.95; 95% CI, 0.92 to 0.97). The absolute mortality reduction was greatest in the most elderly group, those over the age of 80 years. Conclusions— In-hospital mortality after percutaneous coronary intervention has fallen for all age groups over the past 6 years. However, the largest absolute reduction was seen among patients 80 years of age or older.
Methods for Analysis in Pharmacogenomics: Lessons from the Pharmacogenetics Research Network Analysis Group
Srinivasan, Balaji S., Conti, David V. , Gu, Xiangjun, Haines, Jonathan L., Jorgenson, Eric , Kraja, Aldi T., Lasky‐Su, Jessica , Li, Lang , Rodin, Andréi S. , Province, Mike, Ritchie, Marylyn D. , Province, Michael A. , Chen, Jinbo , Cheng, Cheng , Duan, Shiwei , Fridley, Brooke L. , Wang, Dai , Conti, David V , Lasky-Su, Jessica , Province, Mike

Mayo Clinic

Pharmacogenomics | February 10, 2009 | Volume: 10 | Issue: 2 | Pages: 243-251

10.2217/14622416.10.2.243 | PMID 19207025 Get It

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
Friedberg, Jonathan W. , Cerhan, James R. , Flowers, Christopher R. , Dillon, Hildy, Rogers, Eric S., Hainsworth, John D. , Wong, Elaine K., Zelenetz, Andrew D. , Link, Brian K. , Taylor, Michael D. , Farber, Charles Michael , Vose, Julie M. , Cerhan, James R , Link, Brian K , Zelenetz, Andrew D

Mayo Clinic

Journal of Clinical Oncology | February 9, 2009 | Volume: 27 | Issue: 8 | Pages: 1202-1208

10.1200/jco.2008.18.1495 | PMID 19204203 Get It

Purpose Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States. Patients and Methods The National LymphoCare Study is a multicenter, longitudinal, observational study designed to collect information on treatment regimens and outcomes for patients with newly diagnosed FL in the United States. Patients were enrolled between 2004 and 2007. There is no study-specific prescribed treatment regimen or intervention. Results Two thousand seven hundred twenty-eight subjects were enrolled at 265 sites, including the 80% of patients enrolled from nonacademic sites. Using the Follicular Lymphoma International Prognostic Index (FLIPI), three distinct groups independent of histologic grade could be defined. Initial therapeutic strategy was: observation, 17.7%; rituximab monotherapy, 13.9%; clinical trial 6.1%; radiation therapy, 5.6%; chemotherapy only, 3.2%; chemotherapy plus rituximab, 51.9%. Chemotherapy plus rituximab regimens were: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone, 55.0%; rituximab plus cyclophosphamide, vincristine, and prednisone, 23.1%; rituximab plus fludarabine based, 15.5%; other, 6.4%. The choice to initiate therapy rather than observe was associated with age, FLIPI, stage, and grade (P < .01). Significant differences in treatment (P < .01) across regions of the United States were noted. Contrary to practice guidelines, treatment of stage I FL frequently omits radiation therapy. Conclusion Widely disparate therapeutic approaches are utilized for FL. Initial therapy is deferred in a small subset of patients. There is no single standard of care for the treatment of de novo FL, although antibody use is ubiquitous when therapy is initiated. These disparate approaches to the initial care of patients with FL render a heterogeneous group of patients at relapse.
Clinical and electrodiagnostic correlates of peroneal intraneural ganglia
Sorenson, Eric J. , Spinner, Robert J. , Daube, Jasper R., Young, Nathan P.

Mayo Clinic

Neurology | February 2, 2009 | Volume: 72 | Issue: 5 | Pages: 447-452

10.1212/01.wnl.0000341787.70467.99 | PMID 19188576 Get It

Placement of thoracolumbar pedicle screws using three-dimensional image guidance: experience in a large patient cohort
Nottmeier, Eric W. , Seemer, Will, Young, Phillip M.

Mayo Clinic

Journal of Neurosurgery: Spine | January 2, 2009 | Volume: 10 | Issue: 1 | Pages: 33-39

10.3171/2008.10.spi08383 | PMID 19119930 Get It

Object The goal of this study was to analyze the placement accuracy and complications of thoracolumbar pedicle screws (PSs) inserted using 3D image guidance in a large patient cohort. Methods The authors reviewed the charts of 220 consecutive patients undergoing posterior spinal fusion using 3D image guidance for instrumentation placement. A total of 1084 thoracolumbar PSs were placed using either the BrainLAB Vector Vision (BrainLAB, Inc.) or Medtronic StealthStation Treon (Medtronic, Inc.) image guidance systems. Postoperative CT scanning was performed in 184 patients, allowing for 951 screws to be graded by an independent radiologist for bone breach. All complications resulting from instrumentation placement were noted. Using the intraoperative planning function of the image-guided system, the largest diameter screw possible in each particular case was placed. The screw diameter of instrumentation placed into the L3–S1 levels was noted. Results No vascular or visceral complications occurred as a result of screw placement. Two nerve root injuries occurred in 1084 screws placed, resulting in a 0.2% per screw incidence and a 0.9% patient incidence of nerve root injury. Neither nerve root injury was associated with a motor deficit. The breach rate was 7.5%. Grade 1 and minor anterolateral “tip out” breaches accounted for 90% of the total breaches. Patients undergoing revision surgery accounted for 46% of the patients in this study. Accordingly, 154 screws placed through previous fusion mass could be evaluated using postoperative CT scanning. The breach rate in this specific cohort was 7.8%. A total of 765 PSs were placed into the L3–S1 levels in this study; 546 (71%) of these screws were ≥ 7.5 mm in diameter. No statistical difference in breach rate was noted in PSs placed through revision spinal levels versus nonrevision spinal levels (p = 0.499). Additionally, no increase in breach rate was noted with placement of 7.5-mm-diameter screws. Conclusions Three-dimensional image guidance is a useful adjunct to placement of spinal instrumentation. The complication rate in this study was low, and accurate placement of instrumentation was achieved despite the high percentage of revision surgery cases in our patient population. Additionally, because active fluoroscopy was not used for instrumentation placement, there was minimal to no radiation exposure to the surgeon or operating room staff.
Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma
Kim, Jinhee, Jonasch, Eric, Short, John D., Cai, Shengli , Wen, Sijin , Tsavachidou, Dimitra, Tamboli, Pheroze, Wu, Kevin J. , Marlow, Laura A. , Wood, Christopher G. , Copland, John A. , Walker, Cheryl L. , Kim, Jinhee, Alexander, Angela , Czerniak, Bogdan A. , Do, Kim‐Anh , Marlow, Laura

Mayo Clinic

Clinical Cancer Research | December 31, 2008 | Volume: 15 | Issue: 1 | Pages: 81-90

10.1158/1078-0432.ccr-08-0170 | PMID 19118035 Get It

Abstract Purpose: p27 localization and expression has prognostic and predictive value in cancer. Little is known regarding expression patterns of p27 in renal cell carcinoma (RCC) or how p27 participates in disease progression or response to therapy. Experimental Design: RCC-derived cell lines, primary tumors, and normal renal epithelial cells were analyzed for p27 expression, phosphorylation (T157 of the NLS), and subcellular localization. RCC-derived cell lines were treated with phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitors and effects on p27 localization were assessed. The potential contribution of cytoplasmic p27 to resistance to apoptosis was also evaluated. Results: p27 was elevated in tumors compared with matched controls, and cytoplasmic mislocalization of p27 was associated with increasing tumor grade. Cytoplasmic localization of p27 correlated with phosphorylation at T157, an AKT phosphorylation site in the p27 NLS. In RCC cell lines, activated PI3K/AKT signaling was accompanied by mislocalization of p27. AKT activation and phosphorylation of p27 was associated with resistance to apoptosis, and small interfering RNA knockdown of p27 or relocalization to the nucleus increased apoptosis in RCC cells. Treatment with the PI3K inhibitors LY294002 or wortmannin resulted in nuclear relocalization of p27, whereas mTOR inhibition by rapamycin did not. Conclusions: In RCC, p27 is phosphorylated at T157 of the NLS, with increasing tumor grade associated with cytoplasmic p27. PI3K inhibition (which reduces AKT activity) reduces T157 phosphorylation and induces nuclear relocalization of p27, whereas mTOR inhibition does not. Clinical testing of these findings may provide a rational approach for use of mTOR and PI3K/AKT pathway inhibitors in patients with RCC.
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Karp, Judith E. , Flatten, Karen S., Feldman, Eric J. , Greer, Jacqueline M., Loegering, David A., Ricklis, Rebecca M., Morris, Lawrence E. , Ritchie, Ellen K. , Ironside, Valerie, Talbott, Timothy M., Le, Son B. , Meng, Xue , Schneider, Paula A., Dai, Nga T., Adjei, Alex A. , Gore, Steven D. , Wright, John J., Smith, B. Douglas , Roboz, Gail J. , Levis, Mark J. , Wright, John J., Garrett‐Mayer, Elizabeth , Kaufmann, Scott H.

Mayo Clinic

Blood | December 24, 2008 | Volume: 113 | Issue: 20 | Pages: 4841-4852

10.1182/blood-2008-08-172726 | PMID 19109557 Get It

Abstract The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents. Tipifarnib inhibited signaling downstream of the farnesylated small G protein Rheb and synergistically enhanced etoposide-induced antiproliferative effects in lymphohematopoietic cell lines and acute myelogenous leukemia isolates. We subsequently conducted a phase 1 trial of tipifarnib plus etoposide in adults over 70 years of age who were not candidates for conventional therapy. A total of 84 patients (median age, 77 years) received 224 cycles of oral tipifarnib (300-600 mg twice daily for 14 or 21 days) plus oral etoposide (100-200 mg daily on days 1-3 and 8-10). Dose-limiting toxicities occurred with 21-day tipifarnib. Complete remissions were achieved in 16 of 54 (30%) receiving 14-day tipifarnib versus 5 of 30 (17%) receiving 21-day tipifarnib. Complete remissions occurred in 50% of two 14-day tipifarnib cohorts: 3A (tipifarnib 600, etoposide 100) and 8A (tipifarnib 400, etoposide 200). In vivo, tipifarnib plus etoposide decreased ribosomal S6 protein phosphorylation and increased histone H2AX phosphorylation and apoptosis. Tipifarnib plus etoposide is a promising orally bioavailable regimen that warrants further evaluation in elderly adults who are not candidates for conventional induction chemotherapy. These clinical studies are registered at www.clinicaltrials.gov as #NCT00112853.
The Impact of Discordance Between Biopsy and Pathological Gleason Scores on Survival After Radical Prostatectomy
Boorjian, Stephen A. , Karnes, R. Jeffrey , Crispen, Paul L. , Rangel, Laureano J. , Bergstralh, Eric J., Sebo, Thomas J., Blute, Michael L.

Mayo Clinic

Journal of Urology | December 17, 2008 | Volume: 181 | Issue: 1 | Pages: 95-104

10.1016/j.juro.2008.09.016 | PMID 19012937 Get It

Polymorphism in theIL18Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women
Palmieri, Rachel T., Wilson, Melanie A., Iversen, Edwin S., Clyde, Merlise A. , Calingaert, Brian , Moorman, Patricia G. , Poole, Charles, Anderson, S. Keith , Beesley, Jonathan, Høgdall, Estrid , Carney, Michael E., Chen, Xiaoqing , Chenevix‐Trench, Georgia , Chang‐Claude, Jenny , Cunningham, Julie M. , DiCioccio, Richard A., Easton, Douglas F. , Edlund, Christopher K., Gayther, Simon A. , Goode, Ellen L. , Goodman, Marc T. , Kjær, Susanne K. , Høgdall, Claus , Hopkins, Michael P., Jenison, Eric L., Blaakær, Jan , Lurie, Galina, McGuire, Valerie, Menon, Usha , Moysich, Kirsten B. , Ness, Roberta B., Pearce, Celeste Leigh , Pike, Malcolm C. , Ramus, Susan J. , Rossing, Mary Anne, Song, Honglin , Terada, Keith Y. , VanDenBerg, David, Vierkant, Robert A. , Wang‐Gohrke, Shan , Webb, Penelope M. , Whittemore, Alice S. , Wu, Anna H. , Schildkraut, Joellen M. , Bowtell, David D.L. , Weber, Rachel Palmieri , Anderson, Alisha R. , Anton‐Culver, Hoda , Brewster, Wendy R. , Doherty, Jennifer A. , Gentry‐Maharaj, Aleksandra , Pharoah, Paul D.P. , Ziogas, Argyrios , Berchuck, Andrew , Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 8, 2008 | Volume: 17 | Issue: 12 | Pages: 3567-3572

10.1158/1055-9965.epi-08-0548 | PMID 19064572 Get It

AbstractOver 22,000 cases of ovarian cancer were diagnosed in 2007 in the United States, but only a fraction of them can be attributed to mutations in highly penetrant genes such as BRCA1. To determine whether low-penetrance genetic variants contribute to ovarian cancer risk, we genotyped 1,536 single nucleotide polymorphisms (SNP) in several candidate gene pathways in 848 epithelial ovarian cancer cases and 798 controls in the North Carolina Ovarian Cancer Study (NCO) using a customized Illumina array. The inflammation gene interleukin-18 (IL18) showed the strongest evidence for association with epithelial ovarian cancer in a gene-by-gene analysis (P = 0.002) with a &lt;25% chance of being a false-positive finding (q value = 0.240). Using a multivariate model search algorithm over 11 IL18 tagging SNPs, we found that the association was best modeled by rs1834481. Further, this SNP uniquely tagged a significantly associated IL18 haplotype and there was an increased risk of epithelial ovarian cancer per rs1834481 allele (odds ratio, 1.24; 95% confidence interval, 1.06-1.45). In a replication stage, 12 independent studies from the Ovarian Cancer Association Consortium (OCAC) genotyped rs1834481 in an additional 5,877 cases and 7,791 controls. The fixed effects estimate per rs1834481 allele was null (odds ratio, 0.99; 95% confidence interval, 0.94-1.05) when data from the 12 OCAC studies were combined. The effect estimate remained unchanged with the addition of the initial North Carolina Ovarian Cancer Study data. This analysis shows the importance of consortia, like the OCAC, in either confirming or refuting the validity of putative findings in studies with smaller sample sizes. (Cancer Epidemiol Biomarkers Prev 2008;17(12):3567–72)